Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Am J Hematol. 2021 May 8;96(8):E275–E279. doi: 10.1002/ajh.26202

FIGURE 1:

FIGURE 1:

FIGURE 1:

FIGURE 1:

OS in patients withFLT3-ITD with AF≤0.1 by: (A) Treated with or without FLT3i containing regimen; (B) with or without ASCT inCR1, and (C) impact of NPM1 co-mutation and ASCT in CR1